

**David P. Walling, Ph.D.**  
Collaborative Neuroscience Network, Inc.  
12772 Valley View Street, Suite 3  
Garden Grove, CA 92845  
Tel. (714) 799-7799

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Site Liaison  
Tel. (866) 669-0234  
Fax (208) 575-3169  
Email: [clinicaltrials@btheodore.com](mailto:clinicaltrials@btheodore.com)

**AFFILIATIONS:**

Collaborative Neuroscience Network, Inc.  
19401 S. Vermont Avenue, Suite F-100  
Torrance, CA 90502

Collaborative Neuroscience Network, Inc.  
2600 Redondo Avenue, Suite 500  
Long Beach, CA 90806

Ocean View Psychiatric Health Facility  
2600 Redondo Avenue, Suite 500  
Long Beach, CA 90806

Del Amo Hospital  
23700 Camino del Sol  
Torrance, CA 90505

Community Hospital, Long Beach  
1720 N. Termino Ave  
Long Beach, California 90804

Pacific Research Partners, LLC  
1611 Telegraph Avenue, Suite 1550  
Oakland, CA, 94612

**EDUCATION:**

1983-1985 Associate of Arts in Social Science  
Golden West College, Huntington Beach, California

1985-1986 Bachelor of Arts in Psychology  
California State University at Long Beach

**EDUCATION (continued):**

1987-1989 Master of Science in Counseling  
California State University at Fullerton

1989-1993 Doctor of Philosophy in Counseling Psychology  
University of Southern California, Los Angeles, California, APA Accredited

**INTERNSHIP:**

1992-1993 Internship  
University of Texas Medical Branch, Galveston, Texas, APA Accredited

**CERTIFICATION:**

Clinical Hypnotherapist, 1983  
Cognitive-Behavior Therapy for the Chronic Depressions: The Unipolar Mood Disorders, 1996  
Institute of Virginia Commonwealth University

**LICENSURE:**

California Licensed Marriage, Family & Child Counselor, 1992, License No. MFC29326  
Texas Licensed Psychologist, 1995, License No. 25348 – License placed on inactive status October 2000  
California Licensed Psychologist, 1999, License No. 16657

**PROFESSIONAL EXPERIENCE:**

*Chief Executive Officer and Principle Investigator*, 2000-Present  
Collaborative Neuroscience Network, Garden Grove, Long Beach & Torrance, CA

*Vice President of Clinical Services*, 1997-2000  
Psychiatric Management Resources & Stadt Solutions Pharmacy Corporation, San Diego, CA

*Assistant Professor of Psychiatry and Behavioral Sciences*, 1995-1997  
Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX

*Clinical Director*, 1993-1997  
The Gulf Coast Center Intensive Treatment Program, Galveston, TX

*Research Scientist*, 1993-1995  
Dept. of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX

*Crisis Response Clinician*, 1992  
College Hospital, Costa Mesa, CA

**PROFESSIONAL EXPERIENCE (continued):**

*Primary Therapist*, 1990-1992

Harbor View Adolescent Center, Long Beach, CA

*Marriage, Family, & Child Counselor*, 1991-1992

Huntington Psychotherapy, Huntington Beach, CA

*Clinical Coordinator*, 1989-1990

Bellflower Doctors Hospital, Bellflower, CA

*Clinical Social Worker/Unit Therapist*, 1988-1989

Western Medical Center, Anaheim, CA

*Special Member of the Faculty*, 1993-1996

Graduate School of Biomedical Sciences - University of Texas Medical Branch, Galveston, TX

*Member Psychology Internship Program Committee*, 1993-1997

University of Texas Medical Branch, Galveston, TX

Reviewer for Psychiatric Services (formerly Hospital and Community Psychiatry)

Reviewer for Psychiatry Research

Reviewer for American Journal of Clinical Hypnosis

Reviewer for Southwestern Psychological Association 1996 annual conference

Training in the conduction and administration of the Structured Clinical Interview for Diagnosis (SCID)

**INVESTIGATOR EXPERIENCE:**

Phase I • Alzheimer's Disease • Cognitive Impairment • Bipolar Disorder

Depression • Epilepsy • Generalized Anxiety Disorder

Schizophrenia and Schizoaffective Disorders • Sleep Disorders • Smoking Cessation

**CLINICAL TRIAL EXPERIENCE:**

**Phase I**

*Phase I Alzheimer's*

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of XXX in Subjects With Mild to Moderate Alzheimer's disease

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multiple, Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of XXX in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

***Phase I Depression***

A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Multiple Oral Doses of XXX as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

A Phase I, multi-center, randomized, double-blind placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of ascending high doses of xxx as adjunctive therapy in the treatment of subjects with major depressive disorder

A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Pharmacodynamic Effects of XXX in Major Depressive Disorder Subjects

***Phase I Other Indications***

A Phase I, Two-Period, Two Treatment, Two-Way Steady-State Crossover Bioequivalence Study of XXX Tablets under Fasting Conditions

***Phase I Schizophrenia and Schizoaffective Disorders***

A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending, Multiple Oral Doses of XXX in Clinically Stable Adults with Schizophrenia

A Randomized, Double-Blind, Placebo-controlled, Sponsor Open, Phase Ib Study to Examine the Safety, Tolerability and Pharmacokinetics of XXX in Psychiatrically Stable Subjects with Schizophrenia

A Phase I, Multi-center, Randomized, Double-Blind, Comparator-Controlled Study to Assess the Tolerability, Safety, Efficacy, and Pharmacokinetics of Ascending Multiple Oral Doses of XXX in Adult Subjects with a Diagnosis of Schizophrenia or Schizoaffective Disorder

A Phase I, Comparative, Randomized, 2-way Crossover Bioavailability Study of XXX Tablets and XXX Tablets Under Fasting Conditions at Steady State in Subjects with Schizophrenia

A Phase I Two-Period, Two-Treatment, Open-Label, Two-Way Steady-State Crossover Bioequivalence Study of XXX Extended Release Tablets Under Fasting Conditions in Patients

A Phase I, Open-label parallel arm multiple dose tolerability, pharmacokinetics and safety study in adult patients with Schizophrenia following administration of XXX IM depot formulation once every four weeks

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase I, Parallel-group, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of XXX on QT/QTc in Subjects with Schizophrenia or Schizoaffective Disorder

A Phase I, 2-part, open label, inpatient study to assess the safety and tolerability of multiple ascending doses of XXX in subjects with schizophrenia

A Phase I, Evaluation of The Effects of Sequential Multiple-Dose Regimens of XXX on Cardiac Replolarization in Patients with Schizophrenia

A Phase I, Multi-center, Randomized, Double-Blind, Comparator-Controlled Study to Assess the Tolerability, Safety, Efficacy, and Pharmacokinetics of Ascending Multiple Oral Doses of XXX in Adult Subjects with a Diagnosis of Schizophrenia or Schizoaffective Disorder

A Phase I Study Investigating the Potential Interaction between XXX and Antipsychotic Treatments in Subjects with Schizophrenia or Schizoaffective Disorder

A Phase I, Open-label, Parallel-arm, Two-period, Single-dose Pilot Study to Assess the Pharmacokinetics and the Effect of Food on the Pharmacokinetics of Five Once Weekly Oral Formulations of XXX on Adult Subjects with Schizophrenia

A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of XXX a 3-Month Formulation in Subjects with Schizophrenia

A Phase I, Double Blind, Randomized, Placebo- Controlled Study Evaluating QT/ QTc Intervals Following Administration of XXX and XXX in Subjects With Schizophrenia or Schizoaffective Disorder

A Multi-center Double-Blind, Randomized, Parallel Group, Active-Controlled Tolerability and Safety Study of XXX in Clinically Stable Schizophrenic Outpatients

A Placebo- and Positive-Controlled, Randomized Study, Evaluating Qt and Qtc Intervals Following Administration of Immediate-Release an Atypical Antipsychotic in Subjects with Schizophrenia or Schizoaffective Disorder.

**Phase II-IV**

***Alzheimer's Disease***

A Phase II, 24-month, Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel group Amyloid Imaging Positron Emissions Tomography (PET) and safety study of XXX and XXX Adjuvant in Subjects with Mild to Moderate Alzheimer's Disease

A Phase Iia, Multi-center, Randomized, Double-Blind, Placebo Controlled Study to Investigate Efficacy and Safety of XXX in Patients with Mild to Moderate Alzheimer's disease

**CLINICAL TRIAL EXPERIENCE (continued):**

A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type

A Development of Treatment Satisfaction Measures for Alzheimer's XXX

A Multi-center, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Mild to Moderate Alzheimer's Disease

A Phase II, Double Blind, Randomized, Placebo-Controlled, Multi-center, Dose-Ranging, Parallel-Group, Study to Evaluate the Safety and Efficacy of Oral XXX in Patients with Mild to Moderate Alzheimer's Disease

A Phase IIb Nicotinic Agonist Alzheimer's Disease trial, Dose Ranging, Randomized, Double-Blind, Parallel-Group, Placebo-Controller, Multi-center Study of XXX Used as Add-On to XXX Treatment in Patients with Mild to Moderate Symptoms of Alzheimer's Disease

A Phase III Multi-center, Randomized, Placebo-Controlled, Double-Blind, Twelve-Month Safety and Efficacy Study Evaluating XXX in Patients with Mild-to-Moderate Alzheimer's Disease on XXX

A Phase III, Multi-center, Parallel-Group, Long Term Safety and Tolerability Treatment Trial of XXX in subjects with Alzheimer's Disease who Participated in Study XXX or in Study XXX

A Phase III, Multi-center, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Efficacy And Safety Trial Of XXX in Patients With Mild To Moderate Alzheimer's Disease Who Are Apolipoprotein E 4 Non-Carriers

A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXX in Alzheimer's Disease

A Randomized, Open-Label, Three-Period Cross-Over Study in Healthy Subjects to Compare the Pharmacokinetic Profiles of a 7-Day Application of the XXX to Three Different Skin Sites Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Prodromal Alzheimer's Disease

A One-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Medication Approved for the Treatment of Parkinson's Disease Added to a Medication Approved for Memory Impairment and Dementia Daily in Patients with Mild to Moderate Dementia of the Alzheimer's Type

**CLINICAL TRIAL EXPERIENCE (continued):**

A 24-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Three Dosage Levels of XXX in Outpatients with Mild to Moderate Alzheimer's Disease Treated with a Cholinesterase Inhibitor

A 52 Week, Two-Period, Multi-center, Randomized, Double-Blind, XXX-Referenced, Placebo-Controlled, Efficacy and Safety Study of 3 Dosage Levels of XXX in Outpatients with Mild to Moderate Alzheimer's Disease

***Bipolar Disorder***

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase II Study to Evaluate the Efficacy and Safety of Once a Day XXX 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase II Study to Evaluate the Efficacy and Safety of Once a Day XXX Tablet for Sublingual Administration XXX 0.1 mg, 0.4 mg, and 0.8 mg In the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Patients who are on Lithium and/or Valproate

A Long-Term Open-Label Study of the Safety and Tolerability of XXX in Patients with Bipolar I Disorder

A 6-Month, Open-Label, Flexible-Dosage (150-200 mg/day) Extension Study of the Safety and Efficacy of XXX Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

A Double-blind, Placebo-controlled, Parallel-group, Fixed-dosage Study to Evaluate the Efficacy and Safety of XXX Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I Disorder

A Phase IV, Multi-center, Double-blind, Double-dummy, Randomized, Parallel-group Study to Compare the Tolerability of XXX with XXX During Initial Dose Escalation in Patients with Bipolar Depression

A Double-Blind, Placebo-Controlled Study of XXX in Bipolar Depression

A Randomized, 6-Week, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group study of XXX or XXX for the treatment of Bipolar Depression.

A 24-Week, Flexible-Dose, Open-Label Extension Study of XXX for the Treatment of Bipolar I Depression

A Confirmatory Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Use of an Atypical Antipsychotic in the Treatment of Patients with Bipolar Depression

**CLINICAL TRIAL EXPERIENCE (continued):**

A Multi-center, Double-Blind, Randomized, Placebo-Controlled Trial of the Use of a Novel Antipsychotic in the Treatment of Patients with Bipolar Depression

A Phase II Multi-center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of XXX for Inhalation in Patients with Bipolar I Disorder and Agitation

A Multi-center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of XXX Sustained-Release as Mono-Therapy in Adult Patients with Acute Bipolar Mania

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Research Study to Evaluate the Safety and Efficacy of XXX in Patients with Acute Mania in Bipolar Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multi-center Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release XXX in the Treatment of Subjects with Acute Manic and Mixed Episodes Associated with Bipolar I Disorder

A Multi-center, Randomized, Parallel-Group, Double-Blind, Phase III Comparison of the Efficacy and Safety of an Atypical Antipsychotic to Placebo When Used as Adjunct to Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

A Placebo-Controlled, 21-Day Study of the Safety and Efficacy of XXX for the Treatment of Treatment-Resistant Bipolar I Disorder with an Optional Open Label Extension

A Phase III, Randomized, Placebo-Controlled Study Evaluating the Safety and Outcome of Treatment with a Novel Antipsychotic Subjects with Mania

A Multi-center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of XXX as Add-On Therapy with XXX or XXX in the Treatment of Acute Mania

Anti-Seizure Medication vs. Placebo as Add-On Treatment in Subjects with Bipolar Disorder in the Outpatient Setting

A Three-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended-Release XXX in Patients with Bipolar Disorder

A Three-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended-Release XXX in XXX-Failure Patients with Bipolar Disorder

A Six-Month, Open Label, Multi-center Study of Extended Release XXX in Patients with Bipolar Disorder – an Extension

**CLINICAL TRIAL EXPERIENCE (continued):**

*Depression*

A Phase IIb, Double-blind, Placebo-controlled Study of XXX as Adjunctive Therapy in Major Depressive Disorder

A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, XXX-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of XXX in Acute Treatment of Adults With Major Depressive Disorder

A Randomized, 6-week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of XXX For the Treatment of Major Depressive Disorder with Mixed Features

A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 mg XXX versus Placebo in Adult Subjects with Major Depressive Disorder Followed by a 52-week Open-label Extension

A Phase II, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of XXX in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant

A Phase III, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of XXX in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant

A 12-week, Open-Label Extension Study For the Treatment of Major Depressive Disorder with Mixed Features

A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of XXX in Patients With Treatment Resistant Major Depression

A Phase II, Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed XXX in Patients with Treatment Resistant Major Depression

A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral XXX Combination Therapy in Patients With Major Depressive Disorder

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of XXX as Monotherapy Treatment in Patients with Major Depressive Disorder with an Inadequate Response to Antidepressant Therapy

A Phase III, Randomized Placebo-Controlled, Double-Blind Study of XXX Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to XXX

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase III, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XXX in Subjects with Major Depressive Disorder

A Multi-center, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral XXX Combination Therapy in Patients with Major Depressive Disorder

A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents and A 24-Week, Flexible-Dose, Open-Label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder

A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of XXX after 6 weeks of treatment in Patients with Major Depressive Disorder

A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of XXX in Acute Treatment of Adults with Major Depressive Disorder

An 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study of the Efficacy and Safety of XXX Sublingual Tablets Administered Once Daily in Patients with Major Depressive Disorder (MDD)

A Multi-center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

A Multi-center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Long-Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy

A Phase IIa, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX Augmentation of Antidepressant Therapy in Major Depression

A Double-Blind, Randomized, Multi-center, Placebo-Controlled, Relapse Prevention Study with XXX in Out-Patient Adults with Major Depressive Disorder

A Phase IIIb, 12-Week, Double-Blind, Placebo-Controlled, Multi-center Study Evaluating the Safety and Efficacy of XXX 1MG Bid for Smoking Cessation in Subjects with Depression

A Multi-center, Randomized, Double-Blind, Parallel Group, Active-controlled and Placebo-controlled Efficacy and Safety Study of XXX in Subjects with Major Depressive Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase IIb, Multi-center, Randomized, Double-controlled Efficacy and Safety Study of Adjunctive XXX in Patients with Severe Major Depressive Disorder (MDD) and a History of Poor Response or Tolerability to Antidepressants

A Double-Blind, Placebo-Controlled Project of XXX to XXX Antidepressant Therapy (ADT) among Outpatients with Major Depressive Disorder Who have Responded Inadequately to Prior ADT

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses of XXX in Adult Out subjects with Major Depressive Disorder

A Double-Blind, Placebo-Controlled Study of XXX as Adjunctive Therapy in Major Depressive Disorder

A Double-Blind, Placebo-Controlled Project of XXX Adjunctive to Antidepressant Therapy (ADT) among Outpatients with Major Depressive Disorder who have Responded Inadequately to Prior ADT

A Long-Term, Open-Label Study of XXX in Adult Patients with Major Depressive Disorder

A One Year Open label Study Assessing the Safety of XXX in Patients with Major Depressive Disorder

Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Multi-center Study Examining the Safety, Efficacy and Tolerability of XXX in Subjects with SSRI Resistant Major Depressive Disorder

An Eight-Week, Double-Blind Study To Evaluate The Efficacy, Safety And Tolerability Of Two Fixed Doses Of XXX Once Daily In Combination With XXX Once Daily Compared To XXX Placebo In Combination With XXX Once Daily In Patients With Major Depressive Disorder

A Six-Week, Randomized, Double-Blind, Placebo-Controlled Study of XXX in the Treatment of Adults with Major Depressive Disorder and Concomitant Anxiety

An Eight- Week, Multi-center, Double-Blind, Placebo- and XXX-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of XXX in Patients with Major Depressive Disorder

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of an Atypical Antipsychotic as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Multi-center, Randomized, 24-52-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in the Prevention of Relapse of Depressive Symptoms in Outpatients with Major Depressive Disorder Who Achieved an Initial Response to 12 Weeks of Open Label Treatment with XXX

A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy, Safety, and Tolerability of a Once Daily Novel Antidepressant vs. Placebo in Subjects with Major Depressive Disorder

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of a New Anti-Depressant to Another Anti-Depressant to Placebo in Patients with Major Depressive Disorder.

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study Evaluating Efficacy and Safety of XXX Controlled Release vs. Placebo in Patients with Major Depressive Disorder

A Prospective, Multi-center Study Comparing the Safety and Efficacy of XXX Hcl to Cognitive Behavioral Therapy - Chronic Depression (Cbt-Cd) and Combined XXX and Cbt-Cd for the Acute, Continuation and Maintenance Treatment of Chronic Forms of Depression.

An XXX and Cognitive Behavior Therapy for the Chronic Depressives: Pilot Study

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Eight-Week, Safety and Efficacy Study of a Sleep Medication Compared to Placebo in Subjects with Insomnia Related to Major Depressive Disorder

A Study to Evaluate the Efficacy, Safety and Maintenance Effect of an Atypical Antipsychotic Augmentation of SSRI Mono-Therapy in Young and Older Adult Patients with Unipolar Treatment-Resistant Depression

***Schizophrenia and Schizoaffective Disorders***

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Antipsychotic Efficacy of XXX in Patients with Schizophrenia

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of XXX in Subjects with Acute Exacerbation of Schizophrenia

A Phase II, Multicenter, Double-blind, Randomized, Fixed-dose, Parallel-group, 3-Week, Inpatient Treatment Study to Evaluate the Dose Response Relationship, Safety, Efficacy and Pharmacokinetics of XXX Compared with Placebo, using XXX as a Positive Control, in the Treatment of Acute Exacerbation of Schizophrenia

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase III, Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with XXX Compared with 6-month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Community Setting in the United States

A Double-blind, Placebo-controlled, Randomized Withdrawal Study of XXX for the Maintenance Treatment of Subjects with Schizophrenia

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia

A Randomised, double-blind, parallel-group, explorative study of the safety, tolerability and pharmacokinetics of daily dosing compared to a weekly dosing regime of XXX in patients with schizophrenia

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS)

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia

A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

A Phase III, Multicenter, Double-Blind Comparison of XXX and XXX in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with XXX

A Phase III Open-Label, Multicenter, Rollover, Long-term Study of XXX in Patients with Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX Evaluating Time to Relapse in Subjects With Schizoaffective Disorder

A 12-week, Randomized, Multicenter, Open-label, XXX Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving XXX or XXX

A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents and A 24-Week, Flexible-Dose, Open-Label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase IIa, Multi-center, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Treatment Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Two Fixed Doses of XXX Compared to Placebo, Using XXX as an Active Control, in the Treatment of Acute Exacerbation of Schizophrenia

An Evaluation of the Long-Term Safety, Tolerability and Pharmacokinetics of XXX in Patients with Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS)

A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia

A 17-Week, Phase II, Multi-center, Randomized, Double-Blind Study of Treatment with XXX Combined with Standard of Care Compared to placebo Combined with Standard of Care in the Treatment of Patients with DSM-IV-TR Schizophrenia with Prominent Negative Symptoms

A Phase II, Double-Blind Placebo-Controlled Randomized Withdrawal, Multi-center, Safety and Efficacy Study in Adults with Predominant Negative Symptoms and Clinically Stable Schizophrenia who are Taking Stable Dose of Antipsychotic Medication

A Randomized Phase II, Double-Blind, Placebo-Controlled, Multi-center Study of XXX as Add-on Therapy in Outpatients with Persistent Negative Symptoms of Schizophrenia Treated with A Stable Dose of a Second Generation Antipsychotic

A Phase II, 6-week, Multi-center, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX Once Daily and XXX Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia and extension study

A Phase II, Multi-center, Open-label Study to Assess the Safety and Tolerability of XXX Flexible-dosed as Monotherapy in Adult Patients with Schizophrenia

A Prospective, Randomized, Active-controlled, Rater-blinded, International Study of the Prevention of Relapse Comparing XXX to XXX in Adults with Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse

A Phase IIa, Double-blind, Double-dummy, Placebo-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of XXX in Adult Schizophrenic Patients

A Long-Term, Phase II, Multi-center, Randomized, Open-Label, Comparative Safety Study of XXX vs. Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

**CLINICAL TRIAL EXPERIENCE (continued):**

A Non-Interventional, Exploratory Study Designed to Evaluate the Test-Retest Reliability of the MATRICS Consensus Cognitive Battery When Administered Four Times Over a Four-Week Period in Patients Diagnosed with Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of the Safety and Efficacy of XXX in Outpatient on XXX, XXX, XXX, or XXX with Prominent Negative or Disorganized Thought Symptoms

A 38-Week, Multi-center, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of XXX as Maintenance Treatment

A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of XXX in Patients with Schizophrenia

A Phase III Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of XXX in Acutely Psychotic Subjects with Schizophrenia

A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of XXX as Adjunctive Therapy in Adults with Schizophrenia

A Double-Blind, Placebo-Controlled and Comparator-Controlled Study of XXX in Combination with XXX in Patients with Major Depressive Disorder

A Phase IIa, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Assess Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Oral Multiple Ascending Doses for XXX in Patients with Schizophrenia

A Multiple Dose Bioavailability Study Of XXX Tablets to the Reference Listed Drug Tablets at Steady State in Patients Under Fed Conditions

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of XXX in Acutely Psychotic Patients with Schizophrenia

A Single Dose, Open-Label, Randomized, Two-Period, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of a XXX 3-Month Formulation in Subjects with Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, XXX-Referenced, Parallel-Group Study of XXX in Subjects with Acute Exacerbations of Schizophrenia

A Randomized, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect of XXX vs. XXX in Patients with Schizophrenia Using MATRICS Consensus Cognitive Battery

**CLINICAL TRIAL EXPERIENCE (continued):**

A Long-Term Safety, Tolerability, and Effectiveness of XXX in Subjects with Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Mult-Dose Efficacy and Safety Study of Staccato XXX for Inhalation in Schizophrenia Patients with Agitation

A Sixteen-Week, Multi-center, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of Switching from XXX to XXX in Subjects Diagnosed with Schizophrenia or Schizoaffective Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Fixed Dosages of Extended Release XXX in the Treatment of Subjects with Schizophrenia

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center, Phase II Study of the Efficacy and Safety of XXX in Acutely Psychotic Subjects with Schizophrenia

A 24-Week, Multi-center, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of Oral Doses of XXX and Placebo on Top of an Established Treatment Regimen of Either XXX, XXX or XXX Mono-Therapy in the Treatment of Cognitive Impairment in Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dosages of XXX ER in the Treatment of Subjects with Schizoaffective Disorder

A Multi-center, Open Label, Parallel-Group, Randomized, Flexible Dose Study to Evaluate the Safety and Tolerability of Switching from Existing Atypical Antipsychotics to XXX in Subjects with Schizophrenia or Schizoaffective Disorder

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXX in the Acute Exacerbation of Schizophrenia

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the Safety and Efficacy of XXX Used as Augmentation Therapy in the Treatment of Patients with Chronic Schizophrenia Demonstrating an Inadequate Response to XXX or XXX Mono-Therapy

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato XXX for Inhalation in Schizophrenic Patients with Agitation

A Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXX ER Compared to XXX in Subjects with an Acute Exacerbation Schizophrenia

**CLINICAL TRIAL EXPERIENCE (continued):**

A Predicting Response to XXX Treatment Through Identification of Early-Onset of Antipsychotic Drug Action in Schizophrenia

A Randomized, Double Blind, Multi-center Study to Assess the Antipsychotic and Motor Effects of XXX When Administered in Combination with XXX or XXX to Schizophrenic Subjects

A Six-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, XXX-Referenced, Parallel-Group Study to Assess the Safety and Efficacy, of XXX in Subjects with Acute Exacerbations of Schizophrenia Requiring Hospitalization

A 12-Week, International, Multi-center, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-Release XXX in Patients with Schizophrenia

A Randomized, Double-Blind, Placebo and XXX-Controlled, Multi-center Study to Evaluate the Efficacy and Safety and Tolerability of XXX to Schizophrenic Patients in Acute Exacerbation Followed by a Long-Term Treatment Phase

A Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group Study in Adults with Cognitive Impairment Associated with Schizophrenia (CIAS)

A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexibility Dosed XXX Administered Every Two Weeks in Subjects with Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Three Fixed Doses of a Long Acting Antipsychotic in Subjects with Schizophrenia

A Multi-center, Randomized, Double-Blind, Fixed-Dose, Six-Week Trial of the Efficacy and Safety of an Atypical Antipsychotic in Development Compared with Placebo Using Another Atypical Antipsychotic Positive Control in Subjects with an Acute Exacerbation of Schizophrenia

A Multi-center, Double-Blind, Flexible-Dose, Six-Month Trial Comparing the Efficacy and Safety of an Atypical Antipsychotic in Development with an Atypical Antipsychotic in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled and an Atypical Antipsychotic-Referenced, Parallel-Group Efficacy and Safety Study of Two Fixed Doses of an Atypical Antipsychotic in Development in the Treatment of Schizophrenia.

A Multi-center, Open Label, Flexible-Dose, Parallel-Group Evaluation of the Cataractogenic Potential of an Atypical Antipsychotic and Another Atypical Antipsychotic in the Long-Term Treatment of Patients with Schizophrenia Or Schizoaffective Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Four-Week, Double Blind, Multi-center Study Comparing the Efficacy and Safety of an Atypical Antipsychotic to Another Atypical Antipsychotic in Subjects with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care

A Multi-center, Randomized, Double-Blind Study on the Effects of an Atypical Antipsychotic on Overweight or Obese Patients Treated with Another Atypical Antipsychotic for Schizophrenia or Schizoaffective Disorder

A Double-Blind, Eight-Week, Placebo and an Atypical Antipsychotic-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety, and Tolerability of a Novel Antipsychotic in the Treatment of Patients with Schizophrenia or Schizoaffective Disorder

An Assessment of the Efficacy and Safety of Two Sublingual Doses of a Novel Antipsychotic in Subjects with Schizophrenia (in an Acutely, Exacerbated State) Compared to Placebo in a Multi-center, Randomized, Double-Blind, Fixed-Dose, Six-Week Trial with an Atypical Antipsychotic Positive Control Group

A Six-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group Study of the Efficacy and Safety of Three Dose Levels of a Novel Antipsychotic Compared to Placebo and XXX in Patients with Schizophrenia Who Are Experiencing an Acute Exacerbation of Symptoms

A 12-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Evaluation of a Cognitive Enhancer as Adjunctive Therapy in the Treatment of Cognitive Impairment in Patients with Schizophrenia and Schizoaffective Disorder

A Randomized, Double-Blind Study of the Safety and Efficacy of a Mood Stabilizer Plus an Atypical Antipsychotic vs. an Antipsychotic Alone in the Treatment of Schizophrenia

A Multi-center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Evaluation of the Efficacy of a Flexible Dose of a Mood Stabilizer vs. Placebo as Add-On Therapy in Schizophrenia

A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel-Group Evaluation of the Efficacy and Safety of a Fixed-Dose of a Novel Antipsychotic vs. Placebo vs. XXX in Patients with Schizophrenia

A Trial of One Atypical Antipsychotic vs. Another Atypical Antipsychotic in the Treatment of Schizophrenic and Schizoaffective Subjects with Comorbid Depression

A Multi-center, Double-Blind, Randomized Comparison of the Efficacy and Safety of Two Atypical Antipsychotics in the Treatment of Patients with Schizophrenia

A XXX Qd vs. Bid Dosing in Schizophrenia: A Double-Blind, Parallel-Group, Phase III, Multi-center Study

**CLINICAL TRIAL EXPERIENCE (continued):**

A Multi-center, Double-Blind, Randomized Comparison of XXX and XXX in the Treatment of Hospitalized Subjects with Treatment Resistant Schizophrenia

A Double-Blind Placebo-Controlled, Dose-Response Comparison of the Safety and Efficacy of Three Doses of XXX and Three Doses of XXX in Schizophrenic Patients

An Open Label Assessment of the Long-Term Safety of XXX in the Treatment of Schizophrenic Patients

A Multi-center, Double-Blind, Placebo-Controlled, Randomized, Multiple Fixed-Dose Comparison of XXX and XXX in the Treatment of Hospitalized Subjects with Acute Exacerbation of Chronic or Subchronic Schizophrenia

A Fixed-Dose XXX vs. Placebo in the Treatment of Schizophrenia

A Multi-center, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of an Atypical Antipsychotic in Development Using Another Atypical Antipsychotic Positive Control in Subjects.

A Multi-center, Double-Blind, Randomized, Controlled, Multiple Fixed Dose and Dose Regimen Comparison of XXX and XXX in the Prevention of Psychotic Relapse in Outpatients with Chronic or Subchronic Schizophrenia

An Open Label Assessment of the Long-Term Safety of XXX

***Sleep Disorders***

A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of XXX in Patients with Primary Insomnia characterized by Difficulty in Maintaining Sleep

An Efficacy and Safety of XXX on Sleep Maintenance Insomnia with a Sub-Study of the Effect of XXX on Stable Type II Diabetes Mellitus: A One-Year, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study

An Efficacy and Safety of a Hypnotic Sleep Maintenance Insomnia: A 12-Week Multi-center, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open-Treatment Phase Extension for 40 Weeks

An Evaluation of the Long-Term Efficacy and Safety of a Hypnotic Compared to Placebo, When Both Are Administered Over a Long-Term Period “As Needed” in Patients with Chronic Primary Insomnia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Eight-Week, Safety and Efficacy Study of a Novel Sleep Agent Compared to Placebo in Subjects with Major Depressive Disease and Insomnia

**CLINICAL TRIAL EXPERIENCE (continued):**

An Evaluation of the Long-Term Efficacy and Safety of a Sleep Medication Compared to Placebo, When Both Are Administered Over a Long-Term Period "As Needed" in Patients with Chronic Primary Insomnia (A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center, Phase IIIb Clinical Study)

***Other Indications***

A 28-Week Open Label Extension Study Evaluating the Safety and Tolerability of XXX in Subjects with Mild Cognitive Impairment

A One-Year, Multi-center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of a Medication Prescribed for Memory Impairment and Dementia in Subjects with Mild Cognitive Impairment.

A Novel Anxiolytic vs. Placebo in Generalized Anxiety Disorder. A Randomized Double-Blind Placebo and XXX-Controlled Fixed Dose Parallel-Group Multi-center Study of 10 Weeks

**PUBLICATIONS & ABSTRACTS:**

***Peer Reviewed Publications***

Walling, D., Goodwin, J., & Cole, C. (1998) "Prevalence of Dissociative Disorders in a Transsexual Population." *Journal of Sex Education and Therapy* 23(2); 121-123.

McGurk, S.R., Mueser, K.T., Walling, D., Harvey, P.D. & Meltzer, H.Y. (2004) "Cognitive Functioning Predicts Outpatient Service Utilization in Schizophrenia." *Mental Health Services Research* 6(3); 185-188.

Bishop, S., Walling, D., Dott, S, Folkes, C., & Bucy, T. (1999) "Refining Quality of Life Validating a Five Factor Measure for the Severe Mentally Ill. *International Journal for Quality of Life Research* 8(1-2); 151-160.

Goenjian, AK, Walling, DP, Steinberg, AM, Karayan, I, Najarian, LM, Pynoos, R (2005) Five Years Post-Disaster: A Prospective Study of Posttraumatic Stress and Depressive Reactions among Treated and Untreated Adolescents. *American Journal of Psychiatry* 162(12); 2302-2308.

Walling, D, Baker, J., & Dott, S (1998) "Hypnosis Training in Psychology Graduate Programs: A National Survey. *International Journal of Clinical and Experimental Hypnosis*, 46(2); 150-156.

Walling, D. and Levine, R. (1997) "Power in the Hypnotic Relationship: Therapeutic or Abusive?" *American Journal of Psychotherapy*, 51 (1): 67-76.

**PUBLICATIONS & ABSTRACTS (continued):**

Bishop, S., Walling, D., & Walker, B. (1997) "The Emperor's Clothes: Assessing the Validity of the Tennessee Self-Concept Scale." *Educational and Psychological Measurement*, 57(J), 150-163.

Dott, S., Walling, D., Bishop, S., Bucy, J., & Folkes, C., (1996) "The Efficacy of Short-Term Treatment for Improving Quality of Life A Pilot Study." *Journal of Nervous and Mental Disease*, 507-509.

Walling, D., Baker, J., & Dott, S. (1996) "A National Survey of Hypnosis Training: It's Status in Psychiatric Residencies." *International Journal of Clinical and Experimental Hypnosis*, 44, 184-188.

Walling, D., & Baker, J. (1996) "Hypnosis Training in Psychology Internship Programs." *American Journal of Clinical Hypnosis*, 38. (3) 219-223.

***Other Publications***

Walling, D., & Marsh, D., (In press) "Relapse Prevention in Serious Mental Illness" In F.J. Frese (Ed.). Psychologists and Serious Mental Illness: New Directions in Menial Health Services. San Francisco: Jossey-Bass.

Walling, D. & Dott, S. (1999) "Contemporary Approaches to the Management of Serious Mental illness." Book chapter in P. Vega (Ed.) Behavioral Disease Management. Mannisses Communication.

Walling, D. (1997) "Quality of Life in Behavioral Medicine Research" Book Review- Behavioral Medicine.

Walling, David (1996) "Standards for Long-Term Psychiatric Residential Care." Book Review - *Psychiatric Services*, 47(7), 772.

Walling, David P. (1993) "Self-Concept in High Achieving Women: A Comparison of Medical and Nursing Educators." Doctoral Dissertation. University of Southern California.

***Abstracts***

Walling, DP, Rupnow, M, Canuso, C., Turkoz, I. & Rapaport, M. Improvement in Quality of Life with Risperidone Augmentation in Treatment-Resistant Depression. Abstract in submission to the American Psychiatric Association for the May 2004 Annual Meeting.

Walling, D.P. and Goenjan, L.E. Validation of the Adolescent Quality of Life Scale in Greek Trauma Survivors" Abstract presented at the International Associations for the Study of Traumatic Stress -October 2003.

**PUBLICATIONS & ABSTRACTS (continued):**

Walling, D.P., Bishop, S., and Goenjian, A.K. "Quality of Life: Instrument Validation in Serious Mental Illness" Abstract presented at the International Congress on Schizophrenia Research April 2003 meeting Colorado Springs, CO

Walling, D.P. "Pharmacologic and Psychosocial Treatment for Serious Mental Illness." Abstract presented at the Institute for Psychiatric Services October 2001 annual meeting: Orlando, FL.

Walling, D., Bisbee, C & McGurk, S (Symposium Chair) "Serious Mental Illness: Interventions for Change." Paper: Walling, David "Pharmacologic and Psychosocial Treatment for Serious Mental Illness." Symposium presented at the American Psychological Association: August 2001, San Francisco, CA.

Walling, D.P., McGurk, S. & Meltzer, H.Y. "Quality of Life and Service Use in Schizophrenia" Abstract presented at the International Congress on Schizophrenia Research -May 2001: Whistler, B.C. Abstract published in Schizophrenia Research.

McCleery, G., Walling, D.P., Erskine, S. & Bruce, R. "Antipsychotic Usage and Prescriber Reasoning" Abstract presented at the International Congress on Schizophrenia Research -May 2001; Whistler, B.C. Abstract published in Schizophrenia Research.

Walling, D. Marsh, D. Scheifler, P. & McGurk, S. (Symposium Chair) "Serious Mental Illness: Providing Hope Through Treatment" .Paper: Walling, David & Siry, Deborah. "Pharmacologic Treatment Options for Serious Mental Illness: Providing New Hope" Symposium presented at the American Psychological Association: August 2000, Washington, D.C.

Walling, David "Hypnosis in Medical Treatment: Defining Ethical Boundaries." Paper presented at the American Psychological Association: August 2000, Washington, D.C.

Walling, D, Marsh, D. Scheifler, P. & McGurk, S. (Symposium Chair) "Schizophrenia: Hope for the New Millennium." Paper: Walling, David & Siry, Deborah. "Novel Medications: Changing the Face of Schizophrenia Treatment" Symposium presented at the American Psychological Association; August. 1999 annual conference: Boston, MA.

Walling, D. & Baker, J. "Hypnosis: Education and Training for the Future" Paper presented at the American Psychological Association August, 1999 annual conference: Boston, MA.

Walling, D.P., Klein, C.K., Bishop, S.L. & McCleery, G. "Psychometric Evaluation of a Four Factor Quality of Life Instrument" Paper presented at the National Clinical Drug Evaluation Unit June 1999 annual conference; Boca Raton, FL.

Walling, D., Klein, C & Bruce, R. Quality of Life A Measure of Efficacy in Psychosocial Treatment. Paper presented at the International Congress on Schizophrenia Research 1999 biannual conference: Santa Fe, New Mexico.

**PUBLICATIONS & ABSTRACTS (continued):**

Walling, D., Klein, C & Bruce, R. Factor Analysis of the Q-LES-Q: Validating a Quality of Life Measure. Paper presented at the International Congress on Schizophrenia Research 1999 biannual conference Santa Fe, New Mexico.

Walling, D., Klein, C, Bruce, R., Stephens, J., Erskine, S., Jimenez, R. "Quality of Life in Schizophrenia: The Impact of Symptomatology." Paper presented at the Institute for Psychiatric Services October 1998 annual meeting: Los Angeles, CA.

Walling, D., Klein, C., Bruce, R, Stephens, J., Tepper, A., Jimenez, R. "Validation of the Q-LES-Q for use in Schizophrenia Research and Treatment" Paper presented at the Institute for Psychiatric Services October 1998 annual meeting: Los Angeles, CA.

Walling, D., McGurk, S. Hanson, M, Hollis, J., & Summerfelt, T. (Symposium Chair) "Severe Mental Illness in the Community: Increasing Standards of Care" Paper: Walling, David. "Intensive Outpatient Services for the Severe Mentally Ill: Designing What Works." Symposium presented at the American Psychological Association August, 1998 annual conference: San Francisco, CA.

Walling, D. & Goodwin, J. "Sexual Abuse and Hypnosis: Exploring the Relationship to Svengali." Paper presented at the American Psychological Association for August, 1998 annual conference: San Francisco, CA.

Walling, D., & Goodwin, J. "Hypnosis, Sexual Abuse and the Attendant Relationship." Paper presented at the .American Society of Clinical Hypnosis March 1998 annual meeting: Dallas, TX.

Dott, S., Walling, D., and Rosales, L. "Quality of Life and Novel Antipsychotics" Paper presented at the American Psychiatric Association's Institute on Psychiatric Services October 1997 annual meeting: Washington, D.C.

Walling, D., Dott, S., & Gaston, C. "Service Delivery in Severe Mental Illness: Training Issues for Psychologists." Paper presented at the American Psychological Association -August 1997 annual meeting, Chicago, Illinois.

Walling, D. (Symposium Chair) "Novel Antipsychotics for the Next Millennium: Treatment Advances in Psychosis" Paper: Dott, S. & Walling, D. "Olanzapine in the Treatment of Schizophrenia: A Novel Antipsychotic." Paper presented at the American Psychological Association -August 1997 annual meeting, Chicago, Illinois.

Walling, D. & Goodyear, R. "Supervision Issues in Hypnosis: Drawing on Counseling Psychology Paradigms" Paper presented at the American Psychological Association -August 1997 annual meeting, Chicago, Illinois.

**PUBLICATIONS & ABSTRACTS (continued):**

Bishop, S., Walling, D., Dott, S., & Baker, J. "Sensitivity and Specificity in the Quality of Life Enjoyment and Satisfaction Questionnaire." Paper presented at the American Psychological Association (Div. 5) August 1997 annual meeting, Chicago, Illinois.

Durant, D. & Walling, D. "Recapping the Uses of Hypnosis in the Psychiatric Setting." Paper presented at the American Psychological Association (Div. 30) August 1997 annual meeting, Chicago, Illinois.

Dott, S. & Walling, D. "Quality of Subjective Life Experiences in Schizophrenia-Spectrum Disorders." Paper presented at the International Congress on Schizophrenia Research for April 1997 biennial meeting.

Walling, D. & Dott, S. "Risking it All Sexual Behavior in Schizophrenia." Paper presented at the American Psychiatric Association May 1997 annual meeting, San Diego, CA.

Dott, S., Walling, D., Cole, C., & Meyer, W. "When Schizophrenia and Gender Dysphoria Coexist." Paper presented at the American Psychiatric Association May 1997 annual meeting, San Diego, CA.

Bishop, S., Walling, D., Baker, J., & Dott, S. "Quality of Life Assessment: A Window on Chronic Back Pain Management." Paper presented at the Society of Behavioral Medicine. April 1997 annual meeting, San Francisco, CA.

Walling, D., Baker, J., & Dott, S. "Hypnosis in Academia: National Status." Paper presented at the Society for Clinical and Experimental Hypnosis. November 1996 annual meeting: Tampa, Florida.

Dott, S., Walling, D., Cole, C., & Meyer, J. "Schizophrenia and Gender Dysphoria: Misdiagnosis, Misconceptions and Realities" Paper presented at the Society for the Scientific Study of Sexuality November 1996 annual meeting: Houston, Texas.

Walling, D. & Dott, S. "Quality of Life: Measurement, Importance, and Validity in Schizophrenia." Paper presented at the International Conference on Schizophrenia: Breaking Down the Barriers. October 1996: Vancouver, Canada.

Dott, S. & Walling, D. "Sexual Attitudes, Beliefs and Behaviors in Schizophrenia-Spectrum Disorders." Paper presented at the International Conference on Schizophrenia: Breaking Down the Barriers. October 1996: Vancouver, Canada.

Dott, S. & Walling, D. "Crisis Interventions in the Community." Paper presented at the American Psychiatric Association's Institute on Psychiatric Services October 1996 annual meeting: Chicago, Illinois.

**PUBLICATIONS & ABSTRACTS (continued):**

Durant, D. & Walling, D. "The Schizophrenic Mother in Family Therapy?" Paper presented the American Association of Family Therapy for October 1996 annual meeting: Toronto, Canada.

Walling, D., Walker, B., & Bishop, S. "Self-Concept in High Achieving Women." Paper presented at the Northeastern Division Meeting of the American Educational Research Association. October 1996 annual meeting: Ellenville, New York.

Walling, D., Baker, J., & Dort, S. "Hypnosis Training in the U.S.: Results of a National Survey." Paper presented at the American Psychological Association's (Div. 30) August 1996 annual meeting: Toronto, Canada.

Walling, D., Dott, S., Folkes, C., and Glenn, S. "Quality of Life: Measuring the Success of Partial Hospitalization." Paper presented at the Association for Ambulatory Behavioral Healthcare August 1996 annual meeting Minneapolis, Minnesota.

Dott, S. & Walling, D. "The Ghost of Schizophrenia: Past, Present and Future." Paper presented at the Texas Department of Mental Health and Mental Retardation July 1996 annual meeting: Galveston, Texas.

Folkes, C., Dott, S., & Walling, D. "A Collaborative System: Creating a Continuum of Care Within the Community." Paper presented at the Texas Department of Mental Health and Mental Retardation July 1996 annual meeting: Galveston, Texas.

Dort, S. & Walling, D. "An Ounce of Prevention: What Our Patients Don't Know." Paper presented at the 149th annual meeting of the American Psychiatric Association May 1996: New York.

Walling, D. & Wills, S. "Hypnosis, Metaphor and Psychotherapy: Enhancing Treatment Outcomes." Workshop presented at the Southwestern Psychological Association April 1996 annual meeting: Houston, Texas.

Dott, S., Walling, D., & Folkes, C. "Community Based Alternatives to Psychiatric Hospitalization Efficacy and Outcomes" Paper presented at the American Psychiatric Association's Institute on Psychiatric Services October, 1995: Boston, MA